This study reported the long-term effectiveness and safety of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide in combination with ADT improved the overall survival over the long term with manageable side effects in these patients.

The study evaluated the long-term effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) in patients with metastatic prostate cancer (PC) starting androgen-deprivation therapy (ADT). The data showed that enzalutamide and AA+P should not be combined for patients with metastatic PC starting long-term ADT. Clinically important improvements in survival from the addition of AA+P to ADT can be maintained for longer than 7 years.

This study evaluated the association between statin (cholesterol-lowering drugs) use and survival outcomes in men with advanced prostate cancer (PC) undergoing androgen deprivation therapy (ADT). The data showed that statin use improved the survival outcomes in these patients.

This study compared the effects on patient-reported outcomes (PROs) of using olaparib (Lynparza) plus abiraterone (Zytiga) versus placebo plus abiraterone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study found that adding olaparib to abiraterone in these patients did not significantly impact patient-reported pain and health-related quality of life (HRQOL) compared to abiraterone alone (plus placebo).

This study compared the safety and effectiveness of whole-pelvis radiotherapy (WPRT) and prostate-only radiotherapy (PORT) in patients with node-positive prostate cancer (PC) (PC that has spread to nearby lymph nodes). The study found that WPRT improves survival without relapse in these patients, with more short-term gastrointestinal side effects.

This study evaluated the effectiveness and safety of adding short-term androgen deprivation therapy (ADT) with or without pelvic lymph node radiotherapy (PLNRT) to prostate bed salvage radiotherapy (PBRT) after surgery in patients with prostate cancer (PC). The study found that adding short-term ADT and PLNRT to PBRT significantly improved the survival outcomes without cancer progression in these patients.

This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic.

This study evaluated depression, anxiety, and patterns of mental health care in patients with prostate cancer receiving hormonal therapy such as androgen deprivation therapy (ADT). The data showed that almost half of the patients with prostate cancer receiving ADT diagnosed with depression do not receive a documented mental health treatment.

This study evaluated the effects of olaparib (Lynparza) on pain and the health-related quality of life (HR-QoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations (genetic abnormalities) in DNA repair genes. The data showed that treatment with olaparib was associated with a reduction in pain and improvement in HR-QoL compared with physician’s choice of hormone therapy in these patients.

This study evaluated the effectiveness and safety of actinium-225 [²²⁵Ac]-PSMA-617 (225AcPSMA) after treatment with androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA treatment showed a higher response with manageable effects in these patients.